Microdosimetry is gaining increasing interest in particle therapy. Thanks to the advancements in microdosimeter technologies and the increasing number of experimental studies carried out in hadron therapy frameworks, it is proving to be a reliable experimental technique for radiation quality characterisation, quality assurance, and radiobiology studies. However, considering the variety of detectors used for microdosimetry, it is important to ensure the consistency of microdosimetric results measured with different types of microdosimeters.This work presents a novel multi-thickness microdosimeter and a methodology to characterise the radiation quality of a clinical carbon-ion beam. The novel device is a diamond detector made of three sensitive volumes (SVs) of different thicknesses: 2, 6 and 12m. The SVs, which operate simultaneously, were accurately aligned and laterally positioned within 3 mm. This alignment allowed for a comparison of the results with a negligible impact of the SVs alignment and their lateral positioning, ensuring the homogeneity of the measured radiation quality. An experimental campaign was carried out at MedAustron using a carbon-ion beam of typical clinical energy (284.7 MeV u).The measurement results allowed for a meticulous interpretation of its radiation quality, highlighting the effect of the SV thickness. The consistency of the microdosimetric spectra measured by detectors of different thicknesses is discussed by critically analysing the spectra and the differences observed.The methodology presented will be highly valuable for future experiments investigating the effects of the target volume size in radiobiology and could be easily adapted to the other particles employed in hadron therapy for clinical (i.e. protons) and for research purposes (e.g. helium, lithium and oxygen ions).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1361-6560/ad965e | DOI Listing |
JAMA Netw Open
January 2025
Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.
Importance: Evolving breast cancer treatments have led to improved outcomes but carry a substantial financial burden. The association of treatment costs with the cost-effectiveness of screening mammography is unknown.
Objective: To determine the cost-effectiveness of population-based breast cancer screening in the context of current treatment standards.
J Med Radiat Sci
January 2025
Discipline of Medical Imaging Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
Introduction: Quality assurance (QA) in medical imaging ensures consistently high-quality images at acceptable radiation doses. However, the applicability of the chest X-ray (CXR) QA tool in images with pathology, particularly infectious diseases like COVID-19, has not been explored. This study examines the utility of the European Guidelines for image quality in QA of CXRs with varying severity and types of infectious disease.
View Article and Find Full Text PDFLaryngoscope
January 2025
Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Objectives: To evaluate the impact of delayed postoperative radiotherapy (PORT) on overall survival (OS) in patients with head and neck cancers (HNC).
Data Sources: A systematic review and meta-analysis were conducted by searching MEDLINE, Embase, CENTRAL, Web of Science, and CINAHL databases.
Review Methods: Studies assessing the impact of delayed PORT in adult HNC patients were included.
Curr Opin Urol
December 2024
Division of Urologic Oncology.
Purpose Of Review: This review addresses the evolving role of metastasis-directed therapy (MDT) in the management of oligometastatic and oligoprogressive renal cell carcinoma (RCC). With advances in both surgical techniques and stereotactic ablative radiotherapy (SABR), it is timely to explore how MDT can improve patient outcomes in these distinct disease states. The review highlights the potential of MDT to delay systemic therapy and improve quality of life while noting the lack of randomized clinical trial data guiding its use.
View Article and Find Full Text PDFJ Cancer
January 2025
Department of Radiation Oncology, Nanyang Central Hospital, Nanyang, Henan, 473005, China.
Although single-fraction high-dose-rate brachytherapy (SFHDR-BT) for localized prostate cancer has been attempted in clinical trials, there is currently a lack of relevant medical evidence. It is essential to conduct a systematic analysis of the long-term safety and efficacy of SFHDR-BT. Comprehensive and systematic searches for eligible studies were performed in PubMed, Embase, and the Cochrane Library databases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!